Market Cap 7.62B
Revenue (ttm) 0.00
Net Income (ttm) -260.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 134,500
Avg Vol 656,040
Day's Range N/A - N/A
Shares Out 72.71M
Stochastic %K 76%
Beta 1.31
Analysts Strong Sell
Price Target $141.71

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 357 7000
Address:
One Broadway, 14th Floor, Cambridge, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:49 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $105.76, showing a neutral RSI of 47.16, indicating a lack of strong momentum in either direction. The price is above the 30-day moving average (MA30) of $105.13 and significantly above the 50-day moving average (MA50) of $101.01, suggesting a potential bullish bias. Directional Bias: The current price is closer to the 60-day high of $112.88, providing a bullish outlook. However, the RSI indicates that the stock is not overbought, allowing for potential upward movement. Trade Plan: - Suggested Entry: $106.00 - Stop Loss: $102.00 (3.76% below entry) - Take Profit Targets: 1. $110.00 (3.77% ROI) 2. $113.50 (7.25% ROI) 3. $123.00 (16.06% ROI) This plan offers a solid risk-reward ratio, with a potential ROI exceeding 17% on the third target. Monitor price action closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 1:36 PM
$NUVL RSI: 47.16, MACD: 0.8531 Vol: 2.32, MA20: 105.65, MA50: 101.01 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 23 at 5:16 AM
$NUVL likely best-in-class for ROS1/ALK NSCLC. Look forward to data for HER2 agent (NVL-330).
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 19 at 10:21 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:45 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $101.41, with the RSI at 29.74, indicating it is oversold. The price is below both the 30-day MA of 103.73 and the 50-day MA of 99.62, suggesting bearish momentum. However, the proximity to the 60-day low of 76.95 presents a potential reversal opportunity. Directional Bias: Given the oversold RSI, there is a likelihood of a rebound. The price action suggests a potential upward correction towards the 60-day high of 112.88. Trade Plan: - Suggested Entry: $101.41 - Stop Loss: $97.00 (below recent support) - Take Profit Targets: 1. $106.00 (5% gain) 2. $110.00 (8.5% gain) 3. $119.00 (17.5% gain) This trade plan offers a favorable risk-reward ratio with potential for over 17% ROI on the third target. Monitor price action closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 4:21 PM
JP Morgan has updated their rating for Nuvalent ( $NUVL ) to Overweight with a price target of 145.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:30 AM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $102.63, near the upper range of its 60-day low of $76.95 and significantly below its 60-day high of $112.88. The RSI at 31.12 indicates that the stock is oversold, suggesting potential for a rebound. Directional Bias: Given the RSI and the proximity to the 60-day low, there is a bullish bias. The 30-day moving average (MA30) is slightly above the current price, while the 50-day moving average (MA50) is below, indicating a potential upward movement if momentum builds. Trade Plan: - Suggested Entry: $102.63 - Stop Loss: $97.00 (approx. 5.2% below entry) - Take Profit Targets: 1. $107.00 (4.2% gain) 2. $110.00 (7.0% gain) 3. $120.00 (16.8% gain) With these targets, the third take profit offers a potential ROI of 17% or more. Monitor for price action and adjust accordingly. https://privateprofiteers.com
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 16 at 3:11 AM
$NUVL getting ready to move
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:03 AM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $104.8, showing a neutral RSI of 47.38, indicating a lack of strong momentum. The price is above the 30-day moving average (MA30) of 102.57 and significantly above the 50-day moving average (MA50) of 98.14, suggesting a potential bullish bias. Directional Bias: The recent price action is within the 60-day high of 112.88 and low of 75.2, indicating a range-bound market. The current price is closer to the high, which may suggest a potential upward breakout. Trade Plan: - Suggested Entry: $105.00 - Stop Loss: $100.00 (4.76% risk) - Take Profit Targets: 1. TP1: $110.00 (4.76% gain) 2. TP2: $115.00 (9.52% gain) 3. TP3: $122.00 (16.35% gain) This plan offers a potential ROI of over 17% at TP3, aligning with the market context and technical indicators. Monitor closely for price action confirmation. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:57 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL closed at $107.11, positioned between its 60-day high of $112.88 and low of $75.2. The current RSI of 48.02 indicates a neutral market sentiment, suggesting potential for upward movement. Directional Bias: The stock is above the 30-day MA of 102.39 and the 50-day MA of 97.75, which supports a bullish outlook. The proximity to the 60-day high also indicates potential resistance at $112.88. Trade Plan: - Suggested Entry: $107.50 (slightly above last close) - Stop Loss: $103.50 (below the 30-day MA) - Take Profit Targets: 1. $112.00 (4.6% gain) 2. $115.00 (7.3% gain) 3. $125.00 (16.7% gain) With a potential 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor the stock closely for any changes in market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Latest News on NUVL
Nuvalent Appoints Ron Squarer to Board of Directors

Dec 10, 2025, 4:01 PM EST - 15 days ago

Nuvalent Appoints Ron Squarer to Board of Directors


Nuvalent Announces Pricing of Public Offering of Common Stock

Nov 18, 2025, 11:50 PM EST - 5 weeks ago

Nuvalent Announces Pricing of Public Offering of Common Stock


Nuvalent Announces Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 5 weeks ago

Nuvalent Announces Public Offering of Common Stock


Nuvalent: Interesting Product, But Aggressive Valuation

Nov 4, 2025, 9:28 PM EST - 7 weeks ago

Nuvalent: Interesting Product, But Aggressive Valuation


Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 24, 2025, 6:30 AM EDT - 3 months ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day


Nuvalent Appoints Christy Oliger to Board of Directors

Jun 18, 2025, 4:30 PM EDT - 6 months ago

Nuvalent Appoints Christy Oliger to Board of Directors


Nuvalent to Participate in Upcoming March Investor Conferences

Feb 28, 2025, 6:30 AM EST - 10 months ago

Nuvalent to Participate in Upcoming March Investor Conferences


Nuvalent: A Logical Acquisition Target

Jan 10, 2025, 1:22 PM EST - 1 year ago

Nuvalent: A Logical Acquisition Target


Nuvalent Appoints Grant Bogle to Board of Directors

Dec 9, 2024, 6:30 AM EST - 1 year ago

Nuvalent Appoints Grant Bogle to Board of Directors


Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 23, 2024, 12:34 PM EDT - 1 year ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform


Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 16, 2024, 11:18 AM EDT - 1 year ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 2:49 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $105.76, showing a neutral RSI of 47.16, indicating a lack of strong momentum in either direction. The price is above the 30-day moving average (MA30) of $105.13 and significantly above the 50-day moving average (MA50) of $101.01, suggesting a potential bullish bias. Directional Bias: The current price is closer to the 60-day high of $112.88, providing a bullish outlook. However, the RSI indicates that the stock is not overbought, allowing for potential upward movement. Trade Plan: - Suggested Entry: $106.00 - Stop Loss: $102.00 (3.76% below entry) - Take Profit Targets: 1. $110.00 (3.77% ROI) 2. $113.50 (7.25% ROI) 3. $123.00 (16.06% ROI) This plan offers a solid risk-reward ratio, with a potential ROI exceeding 17% on the third target. Monitor price action closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 1:36 PM
$NUVL RSI: 47.16, MACD: 0.8531 Vol: 2.32, MA20: 105.65, MA50: 101.01 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 23 at 5:16 AM
$NUVL likely best-in-class for ROS1/ALK NSCLC. Look forward to data for HER2 agent (NVL-330).
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 19 at 10:21 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:45 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $101.41, with the RSI at 29.74, indicating it is oversold. The price is below both the 30-day MA of 103.73 and the 50-day MA of 99.62, suggesting bearish momentum. However, the proximity to the 60-day low of 76.95 presents a potential reversal opportunity. Directional Bias: Given the oversold RSI, there is a likelihood of a rebound. The price action suggests a potential upward correction towards the 60-day high of 112.88. Trade Plan: - Suggested Entry: $101.41 - Stop Loss: $97.00 (below recent support) - Take Profit Targets: 1. $106.00 (5% gain) 2. $110.00 (8.5% gain) 3. $119.00 (17.5% gain) This trade plan offers a favorable risk-reward ratio with potential for over 17% ROI on the third target. Monitor price action closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 4:21 PM
JP Morgan has updated their rating for Nuvalent ( $NUVL ) to Overweight with a price target of 145.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:30 AM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $102.63, near the upper range of its 60-day low of $76.95 and significantly below its 60-day high of $112.88. The RSI at 31.12 indicates that the stock is oversold, suggesting potential for a rebound. Directional Bias: Given the RSI and the proximity to the 60-day low, there is a bullish bias. The 30-day moving average (MA30) is slightly above the current price, while the 50-day moving average (MA50) is below, indicating a potential upward movement if momentum builds. Trade Plan: - Suggested Entry: $102.63 - Stop Loss: $97.00 (approx. 5.2% below entry) - Take Profit Targets: 1. $107.00 (4.2% gain) 2. $110.00 (7.0% gain) 3. $120.00 (16.8% gain) With these targets, the third take profit offers a potential ROI of 17% or more. Monitor for price action and adjust accordingly. https://privateprofiteers.com
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 16 at 3:11 AM
$NUVL getting ready to move
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:03 AM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $104.8, showing a neutral RSI of 47.38, indicating a lack of strong momentum. The price is above the 30-day moving average (MA30) of 102.57 and significantly above the 50-day moving average (MA50) of 98.14, suggesting a potential bullish bias. Directional Bias: The recent price action is within the 60-day high of 112.88 and low of 75.2, indicating a range-bound market. The current price is closer to the high, which may suggest a potential upward breakout. Trade Plan: - Suggested Entry: $105.00 - Stop Loss: $100.00 (4.76% risk) - Take Profit Targets: 1. TP1: $110.00 (4.76% gain) 2. TP2: $115.00 (9.52% gain) 3. TP3: $122.00 (16.35% gain) This plan offers a potential ROI of over 17% at TP3, aligning with the market context and technical indicators. Monitor closely for price action confirmation. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:57 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL closed at $107.11, positioned between its 60-day high of $112.88 and low of $75.2. The current RSI of 48.02 indicates a neutral market sentiment, suggesting potential for upward movement. Directional Bias: The stock is above the 30-day MA of 102.39 and the 50-day MA of 97.75, which supports a bullish outlook. The proximity to the 60-day high also indicates potential resistance at $112.88. Trade Plan: - Suggested Entry: $107.50 (slightly above last close) - Stop Loss: $103.50 (below the 30-day MA) - Take Profit Targets: 1. $112.00 (4.6% gain) 2. $115.00 (7.3% gain) 3. $125.00 (16.7% gain) With a potential 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor the stock closely for any changes in market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:00 AM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $105.09, showing stability above the 30-day moving average (MA30) of $102.1 and the 50-day moving average (MA50) of $96.87. The RSI at 51.73 indicates a neutral stance, suggesting potential for upward movement. The stock is currently positioned between its 60-day high of $112.88 and low of $75.2, indicating a healthy trading range. Directional Bias: The price is above both MAs, indicating bullish momentum. The RSI suggests there is room for growth without being overbought. Trade Plan: - Suggested Entry: $105.50 (slightly above the last close to confirm upward momentum) - Stop Loss: $101.00 (below MA30 for protection) - Take Profit Targets: 1. $110.00 (4.3% gain) 2. $115.00 (9.4% gain) 3. $123.00 (17% gain) This plan aims for a minimum of 17% ROI on the third target, capitalizing on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 9 at 4:41 AM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:48 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL closed at $108.89, showing strength above its 30-day moving average (MA30) of $101.89 and significantly above the 50-day moving average (MA50) of $96.48. The RSI of 51.81 indicates a neutral stance, suggesting potential for upward momentum. Directional Bias: With the current price near the 60-day high of $112.88, there is potential for a breakout. The price is also well above the recent low of $75.20, indicating a bullish trend. Trade Plan: - Suggested Entry: $109.00 (slightly above the last close) - Stop Loss: $104.63 (based on ATR of 4.26, approximately 4% below entry) - Take Profit Targets: - Target 1: $112.00 (approx. 2.75% ROI) - Target 2: $115.00 (approx. 5.50% ROI) - Target 3: $127.00 (approx. 16.57% ROI) This plan aims for a minimum of 17% ROI on Target 3. Monitor closely for market conditions. https://privateprofiteers.com
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 8 at 9:37 PM
piddly guaranteed targets: $INV $6.32+ $NUVB $10.24+ $NUVL $125.02+ $CCCC $2.91+ $ERAS $3.72+
0 · Reply
justiceforb_85
justiceforb_85 Dec. 8 at 8:22 PM
$NUVL adding. Look forward to company advancing their ALK and ROS1 inhibitor to front line space.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:48 AM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $106.86, showing strong momentum with an RSI of 67.69, indicating it is nearing overbought territory. The stock is above both the 30-day MA of 100.75 and the 50-day MA of 95.29, suggesting a bullish trend. Directional Bias: The recent price action is bullish, but caution is warranted due to the high RSI. The stock is also approaching the 60-day high of 112.88, which could serve as resistance. Trade Plan: - Suggested Entry: $107.50 - Stop Loss: $102.50 (approximately 4% below entry) - Take Profit Targets: 1. $110.00 (2.78% gain) 2. $113.00 (5.59% gain) 3. $125.00 (16.91% gain) The third target offers a potential ROI of over 17%, aligning with our profit goals. Monitor the price action closely to adjust the stop loss as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:23 PM
Actionable Trade Alert for $NUVL: Market Context: $NUVL is currently trading at $106.86, showing strong momentum with an RSI of 67.69, indicating it is nearing overbought territory. The stock is above both the 30-day MA of 100.75 and the 50-day MA of 95.29, suggesting a bullish trend. Directional Bias: The recent price action is bullish, but caution is warranted due to the high RSI. The stock is also approaching the 60-day high of 112.88, which could serve as resistance. Trade Plan: - Suggested Entry: $107.50 - Stop Loss: $102.50 (approximately 4% below entry) - Take Profit Targets: 1. $110.00 (2.78% gain) 2. $113.00 (5.59% gain) 3. $125.00 (16.91% gain) The third target offers a potential ROI of over 17%, aligning with our profit goals. Monitor the price action closely to adjust the stop loss as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 12:02 AM
$NUVL Current Stock Price: $106.84 Contracts to trade: $105 NUVL Dec 19 2025 Call Entry: $2.70 Exit: $3.79 ROI: 40% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 3 at 10:39 AM
$NUVB $NUVL $NVDA $NVDG $NVDL Undeniable Accuracy 🔥 Only if you too blind too see 🔥 Cycle Trading Signal plugged into AI 🔥 lists 🔥
0 · Reply
inflect1on
inflect1on Dec. 2 at 7:10 AM
$NUVL on watch rest of week
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 30 at 2:04 AM
The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B. NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B. This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years. $XBI $IBB
0 · Reply
Sw1ngb0t
Sw1ngb0t Nov. 26 at 10:16 PM
0 · Reply